<DOC>
	<DOCNO>NCT00144131</DOCNO>
	<brief_summary>This study compare efficacy ( non-inferiority ) darbepoetin alfa ( Aranesp® ) extend dose schedule administration ( EDS ) versus darbepoetin alfa administer per week ( QW ) treatment anemia subject non-myeloid malignancy receive multi-cycle chemotherapy .</brief_summary>
	<brief_title>Flexibility : A Study Assess Impact Darbepoetin Alfa Subjects withNon-Myeloid Malignancies With Anemia Due Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects active nonmyeloid malignancy ( y ) include lymphocytic leukemia Receiving chemotherapy expect receive least 8 additional week cyclic cytotoxic chemotherapy anticipate QW , every week ( Q2W ) every three week ( Q3W ) schedule Anemia due cancer and/or chemotherapy ( screen Hb le 11.0 g/dL ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Subjects acute myelogenous leukemia ( AML ) , chronic myelogenous leukemia ( CML ) , myelodysplastic syndrome ( MDS ) Other underlie hematologic disorder , could cause anemia , nonmyeloid malignancy Active bleeding Severe , unstable , active chronic inflammatory disease ( e.g. , ulcerative disease , peptic ulcer disease , rheumatoid arthritis ) Active , unstable systemic chronic infection Planned elective surgery study significant blood loss expect Known iron deficiency ( consider iron deficient subject must follow : saturate transferrin le 15 % ferritin le 10 ng/mL screen ) Unstable angina , uncontrolled cardiac arrhythmia Hypertension ( diastolic blood pressure great 100 mmHg ) Inadequate renal and/or liver function ( e.g. , creatinine great 2 X upper limit normal ( ULN ) and/or transaminase great 5 X ULN ) History pure red blood cell aplasia Known positive human immunodeficiency virus ( HIV ) test acquire immune deficiency syndrome ( AIDS ) status Known positive antibody response erythropoietic agent Subject know sensitivity erythropoietic agent , study drug , excipients administer study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Chemotherapy , Anemia</keyword>
	<keyword>Aranesp® , rHuEPO</keyword>
	<keyword>Chemotherapy Induced Anemia</keyword>
	<keyword>non-myeloid malignancy</keyword>
	<keyword>Non-Myeloid Malignancies</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>